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Combinations of antiretroviral drugs are used
to reduce the risk of HIV infection after HIV ex-
posure of healthcare workers, particularly after
needle-stick injury. Such prophylaxis is increas-
ingly prescribed in cases of non-healthcare related
exposure [1, 2], partly because the risk for HIV in-
fection after exposure through sexual contact is
similar to the risk after needle-stick injury. The es-
timated risk is highest following receptive anal in-
tercourse (0.008 to 0.032), unprotected receptive
vaginal intercourse (0.0005 to 0.0015), and pene-
trative vaginal intercourse (0.0003 to 0.0009) [3, 4].
In December 1997 the Federal Office of Pub-
lic Health of Switzerland published guidelines that
recommended prophylaxis with antiretroviral
drugs for sexual exposure and needle sharing [5].
A voluntary reporting form accompanied the
guidelines. The use of antiretroviral drugs was
supported in case of unprotected vaginal or anal
sexual intercourse, oral sexual intercourse with
ejaculation, or intravenous drug use with contam-
inated drug injection equipment, provided that the
source of exposure was known to be HIV infected.
The proposed prophylactic regimen was a combi-
nation of a protease inhibitor (indinavir or nelfi-
navir) with zidovudine and lamivudine.
Objective: To analyse the data from Swiss na-
tionwide voluntary reporting on non-occupational
HIV-postexposure prophylaxis (HIV-PEP) by
prescribing physicians.
Methods: One hundred and seventy-six per-
sons, who received antiretroviral prophylaxis for
community exposure to HIV between December
1997 and March 2000, were included in this
prospective cohort study with standardised data
collection. Information on the source, the exposed
person, type of exposure, treatment, and outcome
was reported by physicians on a voluntary basis to
three co-ordinating centers.
Results: HIV-PEP was prescribed predomi-
nantly following sexual exposure (69%). Needle
injury was the second most common type of expo-
sure (19% of all exposures), mostly occurring in a
non-healthcare related “professional” setting (ie,
housekeepers, concierges [caretakers], and police-
men). Needle sharing accounted for only 4% of all
cases of exposure. The HIV status of the source
often remained unknown (56%). Most patients re-
ceived a combination of three antiretroviral drugs
(zidovudine/lamivudine/nelfinavir in 34.1%; zi-
dovudine/lamivudine/indinavir in 22.8%; zidovu-
dine/lamivudine/nevirapine in 18.6%; various
triple combinations in 13.8%). Follow-up infor-
mation was available for 86 patients. In this group
78 (91%) completed at least one week of prophy-
laxis. Side-effects were common (70.9%), particu-
larly diarrhoea (29.6%) and nausea (20.9%). Two
patients experienced severe side effects, nephro-
lithiasis with sepsis, and toxic hepatitis, respec-
tively.
Conclusions: In most of the cases where HIV-
PEP was prescribed the indication was question-
able, with the HIV status of the source unknown.
The role of HIV-PEP as part of HIV prevention
programs should be well defined in view of the cost
and potential for causing severe side-effects. 
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Summary
Introduction
In this article, we report on 176 persons who
were prescribed HIV-postexposure prophylaxis
(HIV-PEP) between December 1997 and March
2000. We examined the setting of exposure, pro-
phylaxis prescribed and extent to which source
HIV status was known.
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Methods
Physicians were asked to report detailed information
about non-occupational HIV-PEP prescription by com-
pleting the questionnaire published with the official
guidelines. This questionnaire was standardised and de-
rived from a similar form designed for healthcare related
professional postexposure prophylaxis [6]. German,
French, or Italian versions of the form were used.
The following information was collected on the
source of exposure (HIV status, suspected mode of HIV-
infection, stage of HIV disease, current treatment), the ex-
posed person (age, gender, profession), the exposure itself
(timing, type of sexual exposure, type of injury, needle ex-
change), and treatment (regimen, side-effects). This was a
passive surveillance system which also required physicians
to provide follow-up HIV serology at 3, 6 and 9 months
after exposure.
Forms were sent to one of the three co-ordinating
centres (Zurich, Lausanne, and Lugano). Reports were
validated by one of the study investigators and data were
entered in an MS-Access 1997 database (Microsoft Cor-
poration). Statistical analysis was conducted with SPSS
version 10 (SPSS Inc., Chicago, Illinois).
Results
The characteristics of 176 reportedly exposed
persons between December 1997 and March 2000
are described in table 1. Most patients were male
(62%) and relatively young (median age: 30 years).
The majority of reports came from the French
speaking part of Switzerland (70%). HIV-PEP was
prescribed mostly following sexual exposure
(69%), including rape, and more frequently among
heterosexual partners (table 2). Condom rupture
was the main cause of exposure among heterosex-
uals (71% in this group), whereas unprotected sex
was most common among homosexual males (56%
in this group). Nine persons (2 males and 7 fe-
males) were treated after they were raped. Needle
injury was the second most common type of expo-
sure (19% of all exposures). More than half of the
needle injuries (57%) occurred in a non-healthcare
related occupational setting, ie, in persons who
were at work when they were injured (housekeep-
ers, caretakers, policemen). Needle sharing repre-
sented a small proportion (4%) of all exposures.
The average time interval between exposure and
prescription of HIV-PEP was 25.2 hours (± 2.9
hours; median: 18 hours; range: 45 minutes –168
hours).
The HIV status of the source was only known
for 78 (44%) of the exposed persons (table 3). This
proportion was lower among persons who sus-
tained a needle injury (26%) and victims of rape
(26%). Among 71 source-persons known to be
HIV-positive, 12 (17%) were related to exposure
via homosexual sex, 10 (14%) IVDU with needle
sharing, and 43 (60%) heterosexual sex. Among 38
source-persons with known CDC stage, 25 (66%)
were in CDC stage A, 6 (16%) in stage B, and 7
(18%) in stage C. Information of CD4 cell counts
was available for 38 patients and information of vi-
raemia for 40. Median CD4 counts were 410 cells
per mm3 (range: 30–1453) and 19 (47%) patients
had a viral load below 400 copies/mL (range:
<400–750,000). Information about the treatment
of the source of exposure was available for 28 per-
sons. All but 9 (on zidovudine plus lamivudine or
in one case zidovudine plus didanosine) were re-
ceiving highly active antiretroviral therapy, con-
Characteristic N (%)
Gender Male 110 (62)
Female 61 (35)
Unknown 5 (3)
Median age [range] 30 [9–71]
Language region German (Italian  =  7) 52 (30)
French 124 (70)
Year of reporting 1997* 6 (3)
1998 80 (46)
1999 72 (41)
2000** 18 (10)
* Reporting started in December 1997
** Up to March 2000
Table 1
Characteristics of 
patients prescribed
HIV-postexposure
prophylaxis in
Switzerland, 
1997–2000 
(N = 176).
Exposure N (%)
Sexual 122 (69%)
Heterosexual 85 (48%)
Unprotected sex (29%)
Condom rupture/slippage (71%)
Homosexual 28 (16%)
Unprotected sex (56%)
Condom rupture/slippage (44%)
Rape 9 (5%)
Non-sexual 54 (31%)
Needle injury 34 (19%)
“Professional”* (57%)
Infants (10%)
Others (33%)
Needle sharing 7 (4%)
Other 13 (8%)
* Occupational but not healthcare related (housekeepers, 
concierges [caretakers], policemen)
Table 2
Mode of exposure 
of patients pre-
scribed HIV-postex-
posure prophylaxis in
Switzerland, 
1997–2000.
sisting of at least two nucleoside reverse transcrip-
tase inhibitors and a protease inhibitor or a non-
nucleoside reverse transcriptase analogue.
Data on regimens prescribed as HIV-PEP
were reported for 167 (95%) of the exposed per-
sons. Most patients received zidovudine/lamivu-
dine (AZT/3TC: 8, 4.8%), or AZT/3TC in com-
bination with nelfinavir (NFV: 57, 34.1%), indi-
navir (IDV: 38, 22.8%), or nevirapine (NEV: 31,
18.6%). Twenty-three patients (13.8%) received
other triple combinations and one patient (0.6%)
AZT combined with didanosine. For 9 patients no
detailed information was available on the pre-
scribed drugs. Four patients stopped their treat-
ment when information, indicating that the source
of exposure was HIV-negative, became available.
Detailed follow-up information on treatment tol-
erance was only available for 86 patients. In this
group, 78 patients (91%) completed at least one
week of treatment. The most common side-effects
were diarrhoea (30%) and nausea (21%); 71% of
patients experienced at least one type of side-effect
(table 4). Tolerance of the two regimens most 
often prescribed (AZT/3TC/NFV and AZT/
3TC/IDV) was relatively similar with diarrhoea
more common with AZT/3TC/NFV and nausea
with AZT/3TC/IDV. Two patients presented se-
vere side-effects. Nephrolithiasis occurred in a 70-
year-old caretaker exposed through needle-stick
injury of unknown HIV status while working. She
had received AZT/3TC/IDV. She developed pyo-
nephritis, as a result of ureteral obstruction, re-
quiring hospitalisation and surgery. A 31-year-old
laboratory technician, with sexual exposure and
condom rupture, received AZT/3TC/NFV and
developed toxic hepatitis. The HIV status of the
source was not known.
No HIV infection has been notified among
this group of reportedly HIV-exposed persons.
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HIV status of source
positive negative unknown
(n = 71) (n = 7) (n = 98)
(40%) (4%) (56%)
Year
1997 (6) 50% 0% 50%
1998 (80) 31% 6% 63%
1999 (72) 49% 3% 48%
2000 (17) 47% 0% 53%
Gender of exposed person
Male 35% 2% 63%
Female 49% 8% 43%
Unknown 50% 0% 50%
Exposure
Heterosexual sex 50% 2% 48%
Homosexual sex 43% 0% 57%
Rape 13% 13% 74%
Needle injury 17% 9% 74%
Needle exchange 57% 0% 43%
Language region
German / Italian 39% 4% 57%
French 41% 4% 55%
Table 3
Knowledge of the
source status and
type of exposure of
patients prescribed
non-professional 
HIV-postexposure
prophylaxis in
Switzerland, 
1997–2000.
Regimen AZT/3TC/NFV AZT/3TC/IDV AZT/3TC/NEV Other triple AZT/3TC(DDI) Total 
combinations
N (%) 30 (34.9) 24 (27.9) 16 (18.6) 11 (12.8) 5 (5.8) 86
Side-effect
Diarrhoea 46.7% 25.0% 37.5% 45.5% 0% 29.6%
Nausea 23.3% 37.5% 12.5% 0% 0% 20.9%
Fatigue 20.0% 20.8% 25.0% 18.2% 0% 16.9%
Vomiting 13.3% 12.5% 6.3% 0% 20.0% 10.5%
Headache 3.3% 4.2% 6.3% 9.1% 0% 4.7%
Others* 16.5% 45.8% 25.0% 36.4% 0% 27.9%
Any side-effect 70.0% 79.2% 75.0% 72.7% 20.0% 70.9%
Treatment follow-up 
Modification 0% 25.0% 6.3% 27.3% 0% 11.6%
Interruption** 6.7% 8.3% 6.3% 27.3% 0% 9.3%
* Skin rash, anorexia, insomnia, abdominal pain.
** Due to severe side-effects in two patients: (1) Nephrolithiasis: 70-year-old caretaker with needle-stick injury while working. 
Unknown HIV status of source. Received AZT/3TC/IDV. Required hospitalisation and surgery. (2) Toxic hepatitis: 31-year-old 
laboratory technologist. Sexual exposure with condom rupture. HIV status of source unknown. Received AZT/3TC/NFV.
AZT = zidovudine; 3TC = lamivudine; NFV = nelfinavir; IDV = indinavir; NEV = nevirapine; DDI = didanosine
Table 4
Side-effects and
treatment follow-
up of drug regimens
prescribed as 
HIV-postexposure
prophylaxis in
Switzerland, 
1997–2000, among 86
patients with avail-
able information.
We found that outside the healthcare setting
HIV-postexposure prophylaxis (HIV-PEP) was
prescribed in 122 out of 176 reported cases (69%)
after suspected sexual exposure to HIV. The ob-
servation that HIV status of the source was most
often unknown demonstrates that reported pre-
scriptions often did not comply with official guide-
lines. This finding may be an indication that either
physicians were not aware of these recommenda-
tions or, alternatively that, although these recom-
mendations were epidemiologically sound, they
were not acceptable or applicable. In practice, the
physician’s decision must take into account the pa-
tient’s anxiety and demands. 
Nine persons were prescribed HIV-PEP after
they were raped, although a positive HIV-serology
of the source was known in only one case. In vic-
tims of sexual assault there are often associated fac-
tors which increase the risk of HIV transmission,
particularly trauma, laceration, and bleeding [7].
However, there have been only a few documented
cases of HIV transmission following rape [8]. A
careful evaluation and counselling of the rape vic-
tim, including consideration of the risk-benefit of
HIV-PEP is recommended [9]. The detection of
semen anti-HIV antibodies within the cervico-
vaginal secretions from a rape victim has been re-
ported [10], but the predictive value of this analy-
sis is unknown.
Needle-stick injuries caused 19% of exposures
leading to a HIV-PEP prescription. Although they
occurred outside the healthcare setting, most
(57%) of these exposures involved housekeepers,
caretakers, and policemen in the context of pro-
fessional activity. This emphasises the need for
better education of prescribing physicians and pro-
fessionals about the very low risk of transmission
associated with these exposures. In addition, bet-
ter protective measures against the risk of needle-
stick injuries, eg, gloves and the use of disposal
facilities should be recommended. Notably, HIV
transmission by means of a needle-stick injury out-
side the healthcare setting has not been reported.
Despite the emphasis of the Swiss guidelines on
the low risk of HIV transmission associated with
needle-stick injuries outside the health-care set-
ting, antiretroviral drugs were often prescribed, an
indication of the discrepancy between objective
and subjective risk perception.
Postexposure prophylaxis with antiretroviral
drugs should be initiated as soon as possible but
not later than 72 hours, as it has been recom-
mended for occupational exposures [11]. In our
study, the average time interval between exposure
and prescription of HIV-PEP was 25.2 hours, with
extremes of 45 minutes to 168 hours. Since some
of the studies in animal models suggested no ben-
efit from PEP if started later than 24–36 hours
after HIV exposure [12, 13], there is a need to op-
timise the care of the exposed person to initiate the
antiretroviral prophylaxis as soon as possible.
Almost half (47%) the source patients with
known HIV infection had an undetectable viral
load. Although this situation is likely to be associ-
ated with a lower transmission risk [14], prophy-
laxis with antiretroviral drugs was uniformly pre-
scribed. The vast majority of treated persons re-
ceived a combination of two nucleoside reverse
transcriptase inhibitors and a protease inhibitor.
However, the wide spectrum of antiretroviral
drugs available is reflected in the variety of treat-
ment combinations. Individualisation of the treat-
ment may be justified when the source-patient has
been receiving treatment for some time and re-
sistance to one or more drugs is suspected. Some
experts favour a prophylaxis with two nucleoside
reverse transcriptase inhibitors, eg, zidovudine and
lamivudine, in the majority of situations of non-
occupational HIV exposures [4]. In our experi-
ence, although the numbers are small, this was bet-
ter tolerated than more complex regimens. Addi-
tion of a protease inhibitor would be considered if
the source patient has advanced HIV disease, or is
known to have a plasma viral load >50,000 RNA
copies/ml, or if the source patient has been previ-
ously treated with zidovudine, lamivudine, or
both.
A variety of side-effects of the antiretroviral
therapy were reported in 71% of patients who had
available follow-up information on treatment.
Gastrointestinal symptoms (ie, diarrhoea, nausea,
and vomiting), headache, and fatigue were the
most common side-effects. Intolerance of anti-
retroviral drugs led to premature discontinuation
of treatment or treatment modification in 21% of
cases. Of greater concern, is the observation of two
severe adverse events related to the antiretroviral
drugs, ie, nephrolithiasis complicated by pyo-
nephritis and severe toxic hepatitis. These cases
underscore the importance of a careful evaluation
of the potential danger of antiretroviral prophy-
laxis. In addition, we have recently observed
Stevens-Johnson syndrome in a young physician
exposed to HIV through needle-stick injury, 12
days after starting prophylaxis with nevirapine,
zidovudine and lamivudine (unpublished obser-
vation).
Because reporting of HIV-PEP prescription
was voluntary, it is likely that the reported cases
represent only a fraction of the total number of
non-occupational HIV exposures in Switzerland.
Under-reporting seems even more probable in the
German speaking part of Switzerland. Only one
third of the reports came from this part of the
country where about 65% of the HIV-infected
population lives.
HIV-PEP prescription should be restricted to
situations where the risk of HIV transmission is
well documented and clearly outweighs the risk of
severe side-effects [15]. Although, in certain cir-
cumstances, the use of antiretroviral prophylaxis is
beneficial, HIV-PEP is expensive and potentially
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Discussion
harmful, as demonstrated by our two observations
of severe side-effects. By using a cost-benefit
analysis, Pinkerton and collaborators recom-
mended restricting HIV-PEP following suspected
sexual exposure to regular partners of infected per-
sons, to patients reporting unprotected receptive
anal intercourse, and possibly to situations where
the probability of the partner’s infection is very
high or where the transmission would be unusu-
ally effective, ie, the patient or partner has genital
ulcers or the sex was traumatic [16]. However,
other authors sustain a more permissive view by
recommending antiretrovirals also in the situation
of penetrative vaginal or anal intercourse with a
partner who is or is likely to be HIV infected, and
also offering HIV-PEP in the case of receptive fel-
latio with ejaculation [4].
The use of a rapid HIV test of the source pa-
tient can lower unnecessary intake of antiretrovi-
ral drugs by exposed healthcare workers [17, 18].
Therefore, the feasibility of rapid HIV testing in
the context of non-occupational exposure merits
further attention.
Along with public health messages that em-
phasise safer sex, HIV-PEP can play a role as “sal-
vage preventive strategy”, when primary preven-
tion has failed. Better information aimed at train-
ing physicians about the indications, the risks, and
merits of HIV-PEP, as well as careful documenta-
tion of prescriptions via a national HIV-PEP reg-
istry are indispensable if we are to improve our use
of this important prevention tool.
We thank Annik Maziero for database management
and all the physicians and persons that participated to the
voluntary reporting on non-occupational HIV-postexpo-
sure prophylaxis.
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